DementiaLUMENNCT07347431
Large Language Model for Understanding and Monitoring Elderly Neurocognition
An observational study of Dementia, run by Northumbria Healthcare NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Dementia
- What is being tested?
- LUMEN prototype software interaction
- Type of treatment
- Pill or oral medicine
- How many people
- 60 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 19 Mar 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Study population: Patient and carer dyads: patients attending the Memory Clinic for assessment of cognitive problems. Clinicians: specialist doctors or advanced nurse practitioners responsible for dementia diagnosis
Carers of patients attending Memory Clinic appointments; Aged 18 or over; Both patients and cares can provide informed consent; Basic English literacy
Clinicians must have at least 2 years of specialist dementia care experience and be personally responsible for dementia diagnosis; Must be provide informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
North Tyneside General Hospital is Rake Lane
North Shields, NE29 8NH
Lorelle Dismore, +44191 293 4087, lorelle.dismore@northumbria-healthcare.nhs.uk
About this study
Official title: LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition): A Clinical Feasibility Study With Nested Qualitative Evaluation for AI- Assisted Dementia Assessment
Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.
This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.
Read more
We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.
This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.
Read the detailed description
- Background and Rationale Dementia diagnosis relies on clinical history, cognitive assessments, and collateral information from caregivers. However, obtaining structured and reliable collateral histories is challenging due to caregiver burden, recall bias, and time constraints in memory clinics. Large language models (LLMs) have the potential to improve this process by guiding structured history-taking, extracting clinically relevant details, and standardising information gathering. LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition) is an AI-powered conversational tool designed to assist caregivers in providing structured collateral histories before clinical dementia assessments. Seed-funded by the Royal College of Psychiatrists, the Alzheimer's Research UK Northern Network and the Newcastle Biomedical Research Network, LUMEN was developed to enhance diagnostic accuracy, reduce caregiver burden, and improve workflow efficiency in memory clinics. This study will evaluate the feasibility, usability, and acceptability of LUMEN in real-world clinical settings through a nested qualitative feasibility study. We will recruit caregivers and clinicians to interact with LUMEN and assess its effectiveness in gathering collateral histories. The study will also incorporate co-production workshops with community groups to explore issues around language, cultural inclusivity, and accessibility. Findings will inform future refinements and a larger validation study.
- Research Objectives
This study aims to:
- Evaluate LUMEN's usability -Measure caregiver and clinician experiences using validated scales (System Usability Scale [SUS] and NASA Task Load Index [NASA-TLX]).
- Explore acceptability and implementation barriers and facilitators-Conduct qualitative interviews and coproduction workshops to refine LUMEN's design, ensuring accessibility across diverse user groups.
- Compare LUMEN's outputs to clinician assessments-Investigate the alignment between LUMEN-generated reports and clinician-elicited histories using Cohen's Kappa for inter-rater reliability.
- Background Work Undertaken LUMEN was co-developed with clinicians and stakeholders using a Modified Delphi process involving 150 clinicians, primarily old age psychiatrists. This produced 2,600 questions mapped to validated dementia tools, ensuring clinical relevance. Early technical testing evaluated open-source LLMs (e.g., Mistral 7B, LLaMA2 7B) using simulated clinical vignettes. ROC curve analysis demonstrated an AUC of 0.89 for distinguishing dementia-related narratives, and Cohen's Kappa 0.82 indicated high inter-rater reliability between LUMEN's outputs and clinician ratings. Early PPIE (Patient and Public Involvement and Engagement) feedback highlighted the need for simpler language, cultural sensitivity, and improved user experience. These insights will be further refined through the proposed co-production workshops.
- Study Design and Methodology This study will employ a mixed-methods approach, combining quantitative usability testing with qualitative interviews to evaluate LUMEN's feasibility and acceptability.
4.1. Participants and Recruitment
- Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent.
- Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment.
- Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience.
4.2. Study Procedures
- Baseline Data Collection:
- Demographics (age, gender, ethnicity, socioeconomic status).
- Clinical diagnosis (where available).
- Cognitive test scores (MoCA/ACE).
- LUMEN Interaction:
- Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min).
- Clinicians will review LUMEN-generated histories to assess completeness and clinical utility.
- Usability and Cognitive Load Assessment:
- SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
- NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
- Qualitative Evaluation:
- Semi-structured interviews (n=10 carers, n=4-5 clinicians).
- Co-production workshops with community groups to explore language, cultural representation, and accessibility.
- Exploratory Analysis:
- Inter-rater reliability (Cohen's Kappa): Agreement between LUMEN outputs and clinician assessments.
- Diagnostic accuracy (AUROC curve analysis): Comparison of LUMEN's assessments with clinical diagnoses.
- Milestones and Timescales
The study will run for 12 months (April 2025 - April 2026), with key phases as follows:
Phase Month Activities Preparation \& Ethics 1-3 Final IRAS approval, NHS R\&D approvals, team setup Recruitment \& Data Collection 4-9 Patient-carer dyad recruitment, clinician recruitment, LUMEN testing Usability Workshops 6-8 Co-production workshops, qualitative interviews Data Analysis \& Refinement 9-10 Thematic analysis, SUS/NASA-TLX scoring, LLM refinements Final Reporting \& Next Steps 11-12 Dissemination, grant preparation for large-scale validation study 6. Expected Impact This study will generate critical feasibility data to inform a larger clinical validation study and subsequent NHS integration. Expected outcomes include:
- A refined, co-designed LUMEN prototype with improved usability and accessibility.
- Quantitative evidence on usability and cognitive workload, supporting future funding applications.
- Preliminary insights into AI-assisted collateral history-taking, laying the foundation for regulatory approval as a Software as a Medical Device (SaMD).
- Potential for early NHS adoption under the MHRA framework, streamlining dementia diagnostics.
- Conditions
- Dementia
- Being tested
- LUMEN prototype software interaction
- Keywords
- Dementia, Alzheimer's Disease, Artificial Intelligence, Large Language Models
- Medical subject headings
- Dementia, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LUMEN prototype software interactionOther
This is a prototype software which seeks to gather collateral information relevant to a dementia clinical assessment.
| Study group | Role | What they receive |
|---|---|---|
| Patient-carer dyads | Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent.
• Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment.
1. Baseline Data Collection:
* Demographics (age, gender, ethnicity, socioeconomic status).
* Clinical diagnosis (where available).
* Cognitive test scores (MoCA/ACE).
2. LUMEN Interaction:
o Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min).
3. Usability and Cognitive Load Assessment:
* SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
* NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
4. Qualitative Evaluation:
* Semi-structured interviews (n=10 carers). Receives: Other: LUMEN prototype software interaction | |
| Clinicians | 4.1. Participants and Recruitment
• Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience.
4.2. Study Procedures
1. Baseline Data Collection:
o Demographics (age, gender, ethnicity, socioeconomic status).
2. LUMEN Interaction:
o Clinicians will review LUMEN-generated histories to assess completeness and clinical utility.
3. Usability and Cognitive Load Assessment:
* SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
* NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
4. Qualitative Evaluation:
* Semi-structured interviews (n=4-5 clinicians). Receives: Other: LUMEN prototype software interaction |
What is being measured
The primary outcome is the main question the study is designed to answer.
SUS (System Usability Scale)
10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
Measured: Immediately after use of software
NASA-TLX (Task Load Index):
Evaluates perceived cognitive workload (scores 0-29 = low workload).
Measured: Immediately after prototype interaction
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start19 Mar 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northumbria Healthcare NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- Newcastle University
- Responsible party
- Sponsor
- Investigators
- Judith R Harrison, MBChB PhD, Principal investigator, Northumbria Healthcare NHS Foundation Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07347431
- Sponsor's protocol ID
- NHCT0571
- Acronym
- LUMEN
- Status last verified
- Mar 2026
- First submitted
- 8 Jan 2026
- Last updated
- 21 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: This will include personal narratives of participants' dementia journeys which may contain sensitive information
Study at a glance
From the registry record, last updated by the sponsor on 21 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition): A Clinical Feasibility Study With Nested Qualitative Evaluation for AI- Assisted Dementia Assessment
- ClinicalTrials.gov ID
- NCT07347431
- Acronym / sponsor ID
- LUMEN / NHCT0571
- Conditions
- Dementia
- Keywords
- Dementia, Alzheimer's Disease, Artificial Intelligence, Large Language Models
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Northumbria Healthcare NHS Foundation TrustUniversity, hospital or other
- Collaborators
- Newcastle University
- Study start
- 19 Mar 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Dementia affects millions of people worldwide, and early diagnosis is essential for getting the right care and support. Doctors rely on collateral histories (accounts from family members or caregivers) to understand changes in a person's memory and thinking. However, these histories can be incomplete, unstructured, or difficult to obtain, making diagnosis more challenging.
This study will test LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition), an AI-powered conversation tool designed to help caregivers describe their loved one's symptoms more effectively. By asking structured questions and guiding the conversation, LUMEN can create clear, well-organised reports for memory clinic doctors. This could make assessments quicker, more accurate, and less stressful for families.
We will test LUMEN in real-world clinics by asking caregivers and doctors to use it and provide feedback. We want to understand how easy it is to use, whether it could improve the quality of information shared, and how it fits into existing NHS memory clinic processes. We will also run co-production workshops with community groups to ensure the tool is accessible to people from diverse cultural and language backgrounds.
This research is exciting because it explores how artificial intelligence can improve dementia care. If successful, LUMEN could enhance the diagnostic process, reduce carer burden, and help more people access dementia support sooner. In the future, this tool could be used nationwide in memory clinics, improving care for thousands of families.
Detailed description
- Background and Rationale Dementia diagnosis relies on clinical history, cognitive assessments, and collateral information from caregivers. However, obtaining structured and reliable collateral histories is challenging due to caregiver burden, recall bias, and time constraints in memory clinics. Large language models (LLMs) have the potential to improve this process by guiding structured history-taking, extracting clinically relevant details, and standardising information gathering. LUMEN (Large Language Model for Understanding and Monitoring Elderly Neurocognition) is an AI-powered conversational tool designed to assist caregivers in providing structured collateral histories before clinical dementia assessments. Seed-funded by the Royal College of Psychiatrists, the Alzheimer's Research UK Northern Network and the Newcastle Biomedical Research Network, LUMEN was developed to enhance diagnostic accuracy, reduce caregiver burden, and improve workflow efficiency in memory clinics. This study will evaluate the feasibility, usability, and acceptability of LUMEN in real-world clinical settings through a nested qualitative feasibility study. We will recruit caregivers and clinicians to interact with LUMEN and assess its effectiveness in gathering collateral histories. The study will also incorporate co-production workshops with community groups to explore issues around language, cultural inclusivity, and accessibility. Findings will inform future refinements and a larger validation study.
- Research Objectives
This study aims to:
- Evaluate LUMEN's usability -Measure caregiver and clinician experiences using validated scales (System Usability Scale [SUS] and NASA Task Load Index [NASA-TLX]).
- Explore acceptability and implementation barriers and facilitators-Conduct qualitative interviews and coproduction workshops to refine LUMEN's design, ensuring accessibility across diverse user groups.
- Compare LUMEN's outputs to clinician assessments-Investigate the alignment between LUMEN-generated reports and clinician-elicited histories using Cohen's Kappa for inter-rater reliability.
- Background Work Undertaken LUMEN was co-developed with clinicians and stakeholders using a Modified Delphi process involving 150 clinicians, primarily old age psychiatrists. This produced 2,600 questions mapped to validated dementia tools, ensuring clinical relevance. Early technical testing evaluated open-source LLMs (e.g., Mistral 7B, LLaMA2 7B) using simulated clinical vignettes. ROC curve analysis demonstrated an AUC of 0.89 for distinguishing dementia-related narratives, and Cohen's Kappa 0.82 indicated high inter-rater reliability between LUMEN's outputs and clinician ratings. Early PPIE (Patient and Public Involvement and Engagement) feedback highlighted the need for simpler language, cultural sensitivity, and improved user experience. These insights will be further refined through the proposed co-production workshops.
- Study Design and Methodology This study will employ a mixed-methods approach, combining quantitative usability testing with qualitative interviews to evaluate LUMEN's feasibility and acceptability.
4.1. Participants and Recruitment
- Carers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent.
- Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment.
- Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience.
4.2. Study Procedures
- Baseline Data Collection:
- Demographics (age, gender, ethnicity, socioeconomic status).
- Clinical diagnosis (where available).
- Cognitive test scores (MoCA/ACE).
- LUMEN Interaction:
- Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min).
- Clinicians will review LUMEN-generated histories to assess completeness and clinical utility.
- Usability and Cognitive Load Assessment:
- SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
- NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload).
- Qualitative Evaluation:
- Semi-structured interviews (n=10 carers, n=4-5 clinicians).
- Co-production workshops with community groups to explore language, cultural representation, and accessibility.
- Exploratory Analysis:
- Inter-rater reliability (Cohen's Kappa): Agreement between LUMEN outputs and clinician assessments.
- Diagnostic accuracy (AUROC curve analysis): Comparison of LUMEN's assessments with clinical diagnoses.
- Milestones and Timescales
The study will run for 12 months (April 2025 - April 2026), with key phases as follows:
Phase Month Activities Preparation \& Ethics 1-3 Final IRAS approval, NHS R\&D approvals, team setup Recruitment \& Data Collection 4-9 Patient-carer dyad recruitment, clinician recruitment, LUMEN testing Usability Workshops 6-8 Co-production workshops, qualitative interviews Data Analysis \& Refinement 9-10 Thematic analysis, SUS/NASA-TLX scoring, LLM refinements Final Reporting \& Next Steps 11-12 Dissemination, grant preparation for large-scale validation study 6. Expected Impact This study will generate critical feasibility data to inform a larger clinical validation study and subsequent NHS integration. Expected outcomes include:
- A refined, co-designed LUMEN prototype with improved usability and accessibility.
- Quantitative evidence on usability and cognitive workload, supporting future funding applications.
- Preliminary insights into AI-assisted collateral history-taking, laying the foundation for regulatory approval as a Software as a Medical Device (SaMD).
- Potential for early NHS adoption under the MHRA framework, streamlining dementia diagnostics.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patient-carer dyads | – | Other: LUMEN prototype software interactionCarers (n=20-30 dyads): Recruited via Northumbria NHS Memory Clinics. Eligible carers will be adults (≥18 years) who know the patient well, have basic English literacy, and can provide informed consent. • Patients (n=20-30): Individuals (≥65 years) attending a memory clinic for cognitive assessment. 1. Baseline Data Collection: * Demographics (age, gender, ethnicity, socioeconomic status). * Clinical diagnosis (where available). * Cognitive test scores (MoCA/ACE). 2. LUMEN Interaction: o Carers will use LUMEN on a laptop or tablet to provide structured collateral histories (~20-30 min). 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=10 carers). |
| Clinicians | – | Other: LUMEN prototype software interaction4.1. Participants and Recruitment • Clinicians (n=8-10): Specialists in dementia care (neurologists, psychiatrists, geriatricians, advanced nurse practitioners) with ≥2 years of experience. 4.2. Study Procedures 1. Baseline Data Collection: o Demographics (age, gender, ethnicity, socioeconomic status). 2. LUMEN Interaction: o Clinicians will review LUMEN-generated histories to assess completeness and clinical utility. 3. Usability and Cognitive Load Assessment: * SUS (System Usability Scale): 10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability). * NASA-TLX (Task Load Index): Evaluates perceived cognitive workload (scores 0-29 = low workload). 4. Qualitative Evaluation: * Semi-structured interviews (n=4-5 clinicians). |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
- Study population
- Patient and carer dyads: patients attending the Memory Clinic for assessment of cognitive problems. Clinicians: specialist doctors or advanced nurse practitioners responsible for dementia diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LUMEN prototype software interactionThis is a prototype software which seeks to gather collateral information relevant to a dementia clinical assessment. | Other | Clinicians, Patient-carer dyads |
Primary outcome
SUS (System Usability Scale)
Time frame: Immediately after use of software
10-item Likert-scale questionnaire assessing ease of use (score ≥70 = good usability).
NASA-TLX (Task Load Index):
Time frame: Immediately after prototype interaction
Evaluates perceived cognitive workload (scores 0-29 = low workload).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Apr 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. This will include personal narratives of participants' dementia journeys which may contain sensitive information
Related trials for Dementia
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Judith R Harrison, MBChB PhD principal investigator
Northumbria Healthcare NHS Foundation Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dementia, run by Northumbria Healthcare NHS Foundation Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Judith R Harrison, MBChB (+441912081314, Judith.Harrison@newcastle.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SUS (System Usability Scale) (time frame: Immediately after use of software). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Apr 2026.